FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eileen Dolan

Research Profile

Chemicals & Drugs

Genes & Molecular Sequences

Occupations

Pharmacogenetics

Anatomy

Physiology

Living Beings

Procedures

Genome Wide Association Studies

Co-author Network

Publications

TOP 3
Eric Gamazon; Lidija Gorsic; Christine M Hartford; Imge Hulur; Hae K Im; Jatinder K Lamba; Amit K Mitra; Stanley Pounds; Susana Raimondi; Raul C Ribeiro; Jeffrey E Rubnitz; Amy L Stark; Marleen Welsh; Heather E Wheeler; Shan S Wong; Wei Zhang; Dario Campana; Xueyuan Cao; Nancy J Cox; Kristine R Crews; M Eileen Dolan
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Amy L Stark; M Eileen Dolan
Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?
Eric Gamazon; Hae Kyung Im; Anuar Konkashbaev; Wendy B London; John M Maris; Navin Pinto; Nancy J Cox; Sharon J Diskin; M Eileen Dolan; Susan L Cohn
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eileen Dolan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Eric Gamazon; Lidija Gorsic; Christine M Hartford; Imge Hulur; Hae K Im; Jatinder K Lamba; Amit K Mitra; Stanley Pounds; Susana Raimondi; Raul C Ribeiro; Jeffrey E Rubnitz; Amy L Stark; Marleen Welsh; Heather E Wheeler; Shan S Wong; Wei Zhang; Dario Campana; Xueyuan Cao; Nancy J Cox; Kristine R Crews; M Eileen Dolan
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Blood 2013;121(21):4366-76.
2013: Amy L Stark; M Eileen Dolan
Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?
Pharmacogenomics 2013;14(5):447-50.
2013: Eric Gamazon; Hae Kyung Im; Anuar Konkashbaev; Wendy B London; John M Maris; Navin Pinto; Nancy J Cox; Sharon J Diskin; M Eileen Dolan; Susan L Cohn
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival.
Journal of the National Cancer Institute 2013;105(4):302-9.
2013: Heather E Wheeler; Nancy J Cox; M Eileen Dolan; Michael L Maitland; Mark J Ratain
Cancer pharmacogenomics: strategies and challenges.
Nature reviews. Genetics 2013;14(1):23-34.
2012: Ashraf G Madian; Heather E Wheeler; Richard Baker Jones; M Eileen Dolan
Relating human genetic variation to variation in drug responses.
Trends in genetics : TIG 2012;28(10):487-95.
2012: Amy L Stark; Heather E Wheeler; Shannon M Delaney; Hae Kyung Im; M Eileen Dolan
Functional consequences of PRPF39 on distant genes and cisplatin sensitivity.
Human molecular genetics 2012;21(19):4348-55.
2012: Dennis C Ko; Joshua M Akey; Mitchell Brittnacher; M Eileen Dolan; Christine Fong; Eric Gamazon; Tarah D Holden; Cassandra Ogohara; Richard A Pfuetzner; Matthew Radey; Kajal P Shukla; Amy L Stark; Dale Whittington; Mark M Wurfel; Samuel I Miller
Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(35):E2343-52.
2012: Peter H O'Donnell; Amy L Stark; Heather E Wheeler; Nancy J Cox; Eric Gamazon; Lidija Gorsic; Rong Stephanie Huang; Hae Kyung Im; Bridget E McIlwee; M Eileen Dolan
Identification of novel germline polymorphisms governing capecitabine sensitivity.
Cancer 2012;118(16):4063-73.
2012: Luis J Leandro-García; Susanna Leskelä; Agnieszka Maliszewska; Veronika Mancikova; Mercedes Robledo; Heather E Wheeler; Elisabeth Avall-Lundqvist; Alberto Cascón; Iñaki Comino-Méndez; Aguirre A de Cubas; M Eileen Dolan; Henrik Gréen; Lucia Inglada-Perez; Carlos Jara; Cristina Rodríguez-Antona
Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(16):4441-8.
2012: Uchenna O Njiaju; Heather E Wheeler; Shannon M Delaney; Eric Gamazon; Lidija K Gorsic; Hae Kyung Im; M Eileen Dolan
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.
Pharmacogenetics and genomics 2012;22(7):498-507.
2012: Navin Robert Pinto; Susan Cohn; M Eileen Dolan
Using germline genomics to individualize pediatric cancer treatments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(10):2791-800.
2012: Yujia Wen; Claudia Wing; Wasim K Bleibel; Shannon M Delaney; Shiwei Duan; Eric Gamazon; Hae Kyung Im; Bridget E McIlwee; Shuangli Mi; M Eileen Dolan
An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.
Human molecular genetics 2012;21(7):1470-80.
2012: Hae Kyung Im; Amy L Stark; Nancy J Cox; Eric Gamazon; Rong Stephanie Huang; M Eileen Dolan
Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer.
PLoS genetics 2012;8(2):e1002525.
2012: Younghee Lee; Ellen Rebman; Nancy J Cox; M Eileen Dolan; Eric Gamazon; Sanghyuk Lee; Yeunsook Lee; Yves A Lussier
Variants affecting exon skipping contribute to complex traits.
PLoS genetics 2012;8(10):e1002998.
2011: Amit K Mitra; William Plunkett; Stanley Pounds; Susana Raimondi; Raul C Ribeiro; Jeffrey E Rubnitz; Dario Campana; Xueyuan Cao; Kristine R Crews; M Eileen Dolan; James Downing; Tanya Feldberg; Varsha Gandhi; Yogita Ghodke; Christine Hartford; Jatinder Lamba
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
The Journal of pharmacology and experimental therapeutics 2011;339(1):9-23.
2011: Christiane Querfeld; Alfred Rademaker; Steven T Rosen; Daniel B Yarosh; Joseph Baron; M Eileen Dolan; Francine Foss; Joan Guitart; David S Pezen; Timothy M Kuzel
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(17):5748-54.
2011: Russell A Wilke; M Eileen Dolan
Genetics and variable drug response.
JAMA : the journal of the American Medical Association 2011;306(3):306-7.
2011: Rong Stephanie Huang; Hae Kyung Im; Yujia Wen; Claudia Wing; Wei Zhang; Dana Ziliak; Wasim K Bleibel; Nancy J Cox; Shiwei Duan; Eric Gamazon; M Eileen Dolan
Population differences in microRNA expression and biological implications.
RNA biology 2011;8(4):692-701.
2011: Navin Robert Pinto; M Eileen Dolan
Clinically relevant genetic variations in drug metabolizing enzymes.
Current drug metabolism 2011;12(5):487-97.
2011: Dana Ziliak; Peter H O'Donnell; Hae Kyung Im; Eric Gamazon; Peixian Chen; Shannon Delaney; Sunita Shukla; Soma Das; Nancy J Cox; Everett E Vokes; Ezra E W Cohen; M Eileen Dolan; Rong Stephanie Huang
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.
Translational research : the journal of laboratory and clinical medicine 2011;157(5):265-72.
2011: Lucy A Godley; John Cunningham; M Eileen Dolan; R Stephanie Huang; Sandeep Gurbuxani; Megan E McNerney; Richard A Larson; Hoyee Leong; Yves lussier; Kenan Onel; Olatoyosi Odenike; Wendy Stock; Kevin P White; Michelle M Le Beau
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.
Seminars in oncology 2011;38(2):215-24.
2011: Federico Innocenti; Nancy J Cox; M Eileen Dolan
The use of genomic information to optimize cancer chemotherapy.
Seminars in oncology 2011;38(2):186-95.
2011: Eric Gamazon; Hae Kyung Im; Peter H O'Donnell; Dana Ziliak; Amy L Stark; Nancy J Cox; M Eileen Dolan; Rong Stephanie Huang
Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity.
Molecular cancer therapeutics 2011;10(3):472-80.
2011: Eric Gamazon; Rong Stephanie Huang; M Eileen Dolan; Nancy J Cox
Copy number polymorphisms and anticancer pharmacogenomics.
Genome biology 2011;12(5):R46.
2010: Amy L Stark; Wei Zhang; Tong Zhou; Peter H O'Donnell; Christine M Beiswanger; Rong Stephanie Huang; Nancy J Cox; M Eileen Dolan
Population differences in the rate of proliferation of international HapMap cell lines.
American journal of human genetics 2010;87(6):829-33.
2010: Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Testicular cancer survivorship: research strategies and recommendations.
Journal of the National Cancer Institute 2010;102(15):1114-30.
2010: Eric Gamazon; Rong Stephanie Huang; Nancy J Cox; M Eileen Dolan
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(20):9287-92.
2010: Dan L Nicolae; Eric Gamazon; Wei Zhang; Shiwei Duan; M Eileen Dolan; Nancy J Cox
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS.
PLoS genetics 2010;6(4):e1000888.
2010: Rong Stephanie Huang; M Eileen Dolan
Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.
Pharmacogenomics 2010;11(4):471-4.
2010: Wei Zhang; M Eileen Dolan
Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.
Pharmacogenomics 2010;11(2):249-56.
2010: Eric Gamazon; Wei Zhang; Anuar Konkashbaev; Shiwei Duan; Emily O Kistner; Dan L Nicolae; M Eileen Dolan; Nancy J Cox
SCAN: SNP and copy number annotation.
Bioinformatics (Oxford, England) 2010;26(2):259-62.
2010: Eric Gamazon; Hae-Kyung Im; Shiwei Duan; Yves lussier; Nancy J Cox; M Eileen Dolan; Wei Zhang
Exprtarget: an integrative approach to predicting human microRNA targets.
PloS one 2010;5(10):e13534.
2010: Eric Gamazon; Wei Zhang; M Eileen Dolan; Nancy J Cox
Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset.
PloS one 2010;5(2):e9366.
2009: Marleen Welsh; Lara M Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; howard mcleod; M Eileen Dolan
Pharmacogenomic discovery using cell-based models.
Pharmacological reviews 2009;61(4):413-29.
2009: Navin Robert Pinto; Susan M Ludeman; M Eileen Dolan
Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.
Pharmacogenomics 2009;10(12):1897-903.
2009: Eric Gamazon; Wei Zhang; Rong Stephanie Huang; M Eileen Dolan; Nancy J Cox
A pharmacogene database enhanced by the 1000 Genomes Project.
Pharmacogenetics and genomics 2009;19(10):829-32.
2009: Shiwei Duan; Shuangli Mi; Wei Zhang; M Eileen Dolan
Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes.
RNA biology 2009;6(4):412-25.
2009: Terzah M Horton; Gaye Jenkins; Debananda Pati; Linna Zhang; M Eileen Dolan; Albert Ribes-Zamora; Alison A Bertuch; Susan M Blaney; Shannon L Delaney; Madhuri Hegde; Stacey L Berg
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Molecular cancer therapeutics 2009;8(8):2232-42.
2009: Peter H O'Donnell; M Eileen Dolan
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(15):4806-14.
2009: Jun Yang; Alessia Bogni; Erin G Schuetz; Mark Ratain; M Eileen Dolan; howard mcleod; Li Gong; Caroline Thorn; Mary Relling; Teri E Klein; Russ B Altman
Etoposide pathway.
Pharmacogenetics and genomics 2009;19(7):552-3.
2009: Federico Innocenti; Deanna L Kroetz; Erin G Schuetz; M Eileen Dolan; Jacqueline Ramírez; Mary Relling; Peixian Chen; Soma Das; Gary Rosner; Mark J Ratain
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2604-14.
2009: Cara A Rabik; Edward B Maryon; Kristen Kasza; John T Shafer; Catherine M Bartnik; M Eileen Dolan
Role of copper transporters in resistance to platinating agents.
Cancer chemotherapy and pharmacology 2009;64(1):133-42.
2009: Luke Harrison; Christopher J Ottley; D Graham Pearson; Céline Roche; Stephen R Wedge; M Eileen Dolan; David R Newell; Michael J Tilby
The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2.
Biochemical pharmacology 2009;77(10):1586-92.
2009: Shiwei Duan; Rong Stephanie Huang; Wei Zhang; Shuangli Mi; Wasim K Bleibel; Emily O Kistner; Nancy J Cox; M Eileen Dolan
Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines.
Pharmacogenomics 2009;10(4):549-63.
2009: Johannes Zuber; Ina Radtke; Timothy S Pardee; Zhen Zhao; Amy R Rappaport; Weijun Luo; Mila E McCurrach; Miao-Miao Yang; M Eileen Dolan; Scott C Kogan; James R Downing; Scott W Lowe
Mouse models of human AML accurately predict chemotherapy response.
Genes & development 2009;23(7):877-89.
2009: Christine M Hartford; Shiwei Duan; Shannon M Delaney; Shuangli Mi; Emily O Kistner; Jatinder K Lamba; R Stephanie Huang; M Eileen Dolan
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.
Blood 2009;113(10):2145-53.
2009: Wasim K Bleibel; Shiwei Duan; Rong Stephanie Huang; Emily O Kistner; Sunita J Shukla; Xiaolin Wu; Judith A Badner; M Eileen Dolan
Identification of genomic regions contributing to etoposide-induced cytotoxicity.
Human genetics 2009;125(2):173-80.
2009: Wei Zhang; Shiwei Duan; Wasim K Bleibel; Steven A Wisel; Rong Stephanie Huang; Xiaolin Wu; Lijun He; Tyson A Clark; Tina X Chen; Anthony Schweitzer; John E Blume; M Eileen Dolan; Nancy J Cox
Identification of common genetic variants that account for transcript isoform variation between human populations.
Human genetics 2009;125(1):81-93.
2009: Wei Zhang; M Eileen Dolan
Use of cell lines in the investigation of pharmacogenetic loci.
Current pharmaceutical design 2009;15(32):3782-95.
2009: Wei Zhang; R Stephanie Huang; Shiwei Duan; M Eileen Dolan
Gene set enrichment analyses revealed differences in gene expression patterns between males and females.
In silico biology 2009;9(3):55-63.
2009: Sunita J Shukla; Shiwei Duan; Xiaolin Wu; Judith A Badner; Kristen Kasza; M Eileen Dolan
Whole-genome approach implicates CD44 in cellular resistance to carboplatin.
Human genomics 2009;3(2):128-42.
2008: Cara A Rabik; Melissa L Fishel; Julianne L Holleran; Kristen Kasza; Mark R Kelley; Merrill J Egorin; M Eileen Dolan
Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress.
The Journal of pharmacology and experimental therapeutics 2008;327(2):442-52.
2008: Rong Stephanie Huang; Shiwei Duan; Emily O Kistner; Christine M Hartford; M Eileen Dolan
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans.
Molecular cancer therapeutics 2008;7(9):3038-46.
2008: Ramamoorthy Nagasubramanian; Ryan J Hansen; Shannon M Delaney; Mathew M Cherian; Leona D Samson; Scott C Kogan; M Eileen Dolan
Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure.
Mutagenesis 2008;23(5):341-6.
2008: Scott Weiss; howard mcleod; David A Flockhart; M Eileen Dolan; Neal L Benowitz; Julie A Johnson; Mark J Ratain; Kathleen M Giacomini
Creating and evaluating genetic tests predictive of drug response.
Nature reviews. Drug discovery 2008;7(7):568-74.
2008: Rong Stephanie Huang; Shiwei Duan; Emily O Kistner; Wei Zhang; Wasim K Bleibel; Nancy J Cox; M Eileen Dolan
Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans.
Pharmacogenetics and genomics 2008;18(6):545-9.
2008: Olatoyosi Odenike; Richard A Larson; Devika Gajria; M Eileen Dolan; Shannon M Delaney; Theodore Karrison; Mark J Ratain; Wendy Stock
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Investigational new drugs 2008;26(3):233-9.
2008: Wei Zhang; M Eileen Dolan
Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations.
Pharmacogenomics 2008;9(5):489-92.
2008: Rong Stephanie Huang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Shannon M Delaney; Donna L Fackenthal; Soma Das; M Eileen Dolan
Genetic variants contributing to daunorubicin-induced cytotoxicity.
Cancer research 2008;68(9):3161-8.
2008: Shiwei Duan; Rong Stephanie Huang; Wei Zhang; Wasim K Bleibel; Cheryl Roe; Tyson A Clark; Tina X Chen; Anthony Schweitzer; John E Blume; Nancy J Cox; M Eileen Dolan
Genetic architecture of transcript-level variation in humans.
American journal of human genetics 2008;82(5):1101-13.
2008: Wei Zhang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Rong Stephanie Huang; Tyson A Clark; Tina X Chen; Anthony Schweitzer; John E Blume; Nancy J Cox; M Eileen Dolan
Evaluation of genetic variation contributing to differences in gene expression between populations.
American journal of human genetics 2008;82(3):631-40.
2008: Sunita J Shukla; Shiwei Duan; Judith A Badner; Xiaolin Wu; M Eileen Dolan
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis.
Pharmacogenetics and genomics 2008;18(3):253-62.
2008: Wei Zhang; M Eileen Dolan
Exploring the evolutionary history of the differentially expressed genes between human populations: action of recent positive selection.
Evolutionary bioinformatics online 2008;4():171-9.
2008: Shiwei Duan; Wei Zhang; Wasim Kamel Bleibel; Nancy Jean Cox; M Eileen Dolan
SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs.
Bioinformation 2008;2(10):469-70.
2008: Wei Zhang; Shiwei Duan; M Eileen Dolan
HapMap filter 1.0: a tool to preprocess the HapMap genotypic data for association studies.
Bioinformation 2008;2(8):322-4.
2008: Wei Zhang; Mark J Ratain; M Eileen Dolan
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.
Bioinformatics and biology insights 2008;2():15-23.
2008: Wei Zhang; M Eileen Dolan
On the challenges of the HapMap resource.
Bioinformation 2008;2(6):238-9.
2007: Terzah M Horton; Patrick A Thompson; Stacey L Berg; Peter Charles Adamson; Ashish Ingle; M Eileen Dolan; Shannon M Delaney; Madhuri Hedge; Heidi L Weiss; Meng-Fen Wu; Susan M Blaney
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(31):4922-8.
2007: Christine M Hartford; M Eileen Dolan
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity.
Pharmacogenomics 2007;8(9):1159-68.
2007: Rong Stephanie Huang; Shiwei Duan; Sunita J Shukla; Emily O Kistner; Tyson A Clark; Tina X Chen; Anthony Schweitzer; John E Blume; M Eileen Dolan
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach.
American journal of human genetics 2007;81(3):427-37.
2007: Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.
DNA repair 2007;6(8):1145-54.
2007: Bakhtiar Yamini; Xiaohong Yu; M Eileen Dolan; Michael H Wu; Thomas E Darga; Donald Kufe; Ralph R Weichselbaum
Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding.
Cancer research 2007;67(14):6889-98.
2007: Rong Stephanie Huang; Shiwei Duan; Wasim K Bleibel; Emily O Kistner; Wei Zhang; Tyson A Clark; Tina X Chen; Anthony Schweitzer; John E Blume; Nancy J Cox; M Eileen Dolan
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(23):9758-63.
2007: Shiwei Duan; Wasim K Bleibel; Rong Stephanie Huang; Sunita J Shukla; Xiaolin Wu; Judith A Badner; M Eileen Dolan
Mapping genes that contribute to daunorubicin-induced cytotoxicity.
Cancer research 2007;67(11):5425-33.
2007: Ryan J Hansen; Ramamoorthy Nagasubramanian; Shannon M Delaney; Leona D Samson; M Eileen Dolan
Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice.
Carcinogenesis 2007;28(5):1111-6.
2007: Jon D Weingart; Stuart A Grossman; Kathryn Carson; Joy D Fisher; Shannon M Delaney; Mark L Rosenblum; Alessandro Olivi; Kevin Judy; Stephen B Tatter; M Eileen Dolan
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(4):399-404.
2007: Cara A Rabik; M Eileen Dolan
Molecular mechanisms of resistance and toxicity associated with platinating agents.
Cancer treatment reviews 2007;33(1):9-23.
2007: Rong Stephanie Huang; Emily O Kistner; Wasim K Bleibel; Sunita J Shukla; M Eileen Dolan
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity.
Molecular cancer therapeutics 2007;6(1):31-6.
2006: Christopher W Ryan; M Eileen Dolan; Bruce B Brockstein; Roger McLendon; Shannon M Delaney; Brian L Samuels; Edem S Agamah; Everett E Vokes
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
Cancer chemotherapy and pharmacology 2006;58(5):634-9.
2006: Cara A Rabik; Maria Chidiamara Njoku; M Eileen Dolan
Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.
Cancer treatment reviews 2006;32(4):261-76.
2006: Melissa L Fishel; Cara A Rabik; Wasim K Bleibel; Xinmin Li; Robert C Moschel; M Eileen Dolan
Role of GADD34 in modulation of cisplatin cytotoxicity.
Biochemical pharmacology 2006;71(3):239-47.
2005: Ryan J Hansen; Ramamoorthy Nagasubramanian; Shannon M Delaney; Mathew M Cherian; Shang Lin; Scott C Kogan; M Eileen Dolan
Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
The Journal of pharmacology and experimental therapeutics 2005;315(3):1247-55.
2005: Boris Pasche; Thomas J Knobloch; Yansong Bian; Junjian Liu; Sharbani Phukan; Diana Rosman; Virginia G Kaklamani; Lisa Baddi; Farida S Siddiqui; Wendy Frankel; Thomas W Prior; David E Schuller; Amit Agrawal; Jas Lang; M Eileen Dolan; Everett E Vokes; William Stratton Lane; Chiang-Ching Huang; Trinidad Caldes; Antonio Di Cristofano; Heather Hampel; IngMarie Nilsson; Gunnar von Heijne; Riccardo Fodde; Vundavalli Murty; Albert de La Chapelle; Christopher M Weghorst
Somatic acquisition and signaling of TGFBR1*6A in cancer.
JAMA : the journal of the American Medical Association 2005;294(13):1634-46.
2005: Jennifer A Quinn; Annick Desjardins; Jon D Weingart; Henry Brem; M Eileen Dolan; Shannon M Delaney; James J Vredenburgh; Jeremy Rich; Allan H Friedman; David A Reardon; John H Sampson; Anthony E Pegg; Robert C Moschel; Robert Birch; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Janet E Dancey; Jill Maxwell; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7178-87.
2005: C Lynn Cheng; Stewart P Johnson; Stephen T Keir; Jennifer A Quinn; Francis Ali-Osman; Csaba Szabó; Hongshan Li; Andrew L Salzman; M Eileen Dolan; Paul Modrich; Darell D Bigner; Henry S Friedman
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Molecular cancer therapeutics 2005;4(9):1364-8.
2005: Sunita J Shukla; M Eileen Dolan
Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies.
Pharmacogenomics 2005;6(3):303-10.
2005: Melissa L Fishel; Michael P Gamcsik; Shannon M Delaney; Eleanor G Zuhowski; Veronica M Maher; Theodore Karrison; Robert C Moschel; Merrill J Egorin; M Eileen Dolan
Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.
Cancer chemotherapy and pharmacology 2005;55(4):333-42.
2005: Wanqing Liu; Federico Innocenti; Michael H Wu; Apurva A Desai; M Eileen Dolan; Edwin H Cook; Mark J Ratain
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.
Cancer research 2005;65(1):46-53.
2005: Melissa L Fishel; David R Newell; Roger J Griffin; Richard Davison; Lan-Zhen Wang; Nicola J Curtin; Eleanor G Zuhowski; Kristen Kasza; Merrill J Egorin; Robert C Moschel; M Eileen Dolan
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.
The Journal of pharmacology and experimental therapeutics 2005;312(1):206-13.
2004: Ya Jun Hu; M Eileen Dolan; Richard Bae; Herman Yee; Martin Roy; Robert S Glickman; Lidia Kiremidjian-Schumacher; Alan M Diamond
Allelic loss at the GPx-1 locus in cancer of the head and neck.
Biological trace element research 2004;101(2):97-106.
2004: Michael H Wu; Peixian Chen; Xiaolin Wu; Wanqing Liu; Stephen Strom; Soma Das; Edwin H Cook; Gary Rosner; M Eileen Dolan
Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.
Pharmacogenetics 2004;14(9):595-605.
2004: James B Springer; Young H Chang; Kyo I Koo; O Michael Colvin; Michael Colvin; M Eileen Dolan; Shannon M Delaney; James L Flowers; Susan M Ludeman
1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards.
Chemical research in toxicology 2004;17(9):1217-26.
2004: Manny Bacolod; Stewart P Johnson; Anthony E Pegg; M Eileen Dolan; Robert C Moschel; Nancy S Bullock; Qingming Fang; O Michael Colvin; Paul Modrich; Darell D Bigner; Henry S Friedman
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Molecular cancer therapeutics 2004;3(9):1127-35.
2004: M Eileen Dolan; Karla G Newbold; Ramamoorthy Nagasubramanian; Xiaolin Wu; Mark J Ratain; Edwin H Cook; Judith A Badner
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
Cancer research 2004;64(12):4353-6.
2003: Nicholas D Yeager; M Eileen Dolan; Julie M Gastier-Foster; Thomas G Gross; Shannon Delaney; Jessica Frick; Frederick B Ruymann; Reginald Ewesuedo
O6-methylguanine-DNA methyltransferase activity and promoter methylation status in pediatric rhabdomyosarcoma.
Journal of pediatric hematology/oncology 2003;25(12):941-7.
2003: Ramamoorthy Nagasubramanian; M Eileen Dolan
Temozolomide: realizing the promise and potential.
Current opinion in oncology 2003;15(6):412-8.
2003: Sonali M Smith; Susan M Ludeman; Lynette R Wilson; James B Springer; Mihir C Gandhi; M Eileen Dolan
Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells.
Cancer chemotherapy and pharmacology 2003;52(4):291-302.
2003: Melissa L Fishel; Shannon M Delaney; Lindsay D Friesen; Ryan J Hansen; Eleanor G Zuhowski; Robert C Moschel; Merrill J Egorin; M Eileen Dolan
Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.
Molecular cancer therapeutics 2003;2(7):633-40.
2003: Michael H Wu; Peixian Chen; Benjamin F Remo; Edwin H Cook; Soma Das; M Eileen Dolan
Characterization of multiple promoters in the human carboxylesterase 2 gene.
Pharmacogenetics 2003;13(7):425-35.
2002: Henry S Friedman; Stephen T Keir; Anthony E Pegg; Peter J Houghton; O Michael Colvin; Robert C Moschel; Darell D Bigner; M Eileen Dolan
O6-benzylguanine-mediated enhancement of chemotherapy.
Molecular cancer therapeutics 2002;1(11):943-8.
2002: D K Park; Christopher W Ryan; M Eileen Dolan; Nicholas J Vogelzang; Walter M Stadler
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
Cancer chemotherapy and pharmacology 2002;50(2):160-2.
2002: Michael H Wu; Bingfang Yan; Rod A Humerickhouse; M Eileen Dolan
Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2696-700.
2002: M Eileen Dolan; Mitchell Posner; Theodore Karrison; Jonathan M Radosta; Gary Steinberg; Donna Bertucci; Lucky Vujasin; Mark J Ratain
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2519-23.
2002: Jennifer A Quinn; James Pluda; M Eileen Dolan; Shannon M Delaney; Richard S. Kaplan; Jeremy Rich; Allan H Friedman; David A Reardon; John H Sampson; O Michael Colvin; Michael M Haglund; Anthony E Pegg; Robert C Moschel; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2277-83.
2002: Narayanan Balu; Michael P Gamcsik; Michael Colvin; O Michael Colvin; M Eileen Dolan; Susan M Ludeman
Modified guanines representing O(6)-alkylation by the cyclophosphamide metabolites acrolein and chloroacetaldehyde: synthesis, stability, and ab initio studies.
Chemical research in toxicology 2002;15(3):380-7.
2002: M Eileen Dolan; Richard L Schilsky
Silence is golden: gene hypermethylation and survival in large-cell lymphoma.
Journal of the National Cancer Institute 2002;94(1):6-7.
2001: L Long; M Eileen Dolan
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):4239-44.
2001: Y Cai; Susan M Ludeman; Lynette R Wilson; A B Chung; M Eileen Dolan
Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells.
Molecular cancer therapeutics 2001;1(1):21-8.
2001: L Long; Robert C Moschel; M Eileen Dolan
Debenzylation of O(6)-benzyl-8-oxoguanine in human liver: implications for O(6)-benzylguanine metabolism.
Biochemical pharmacology 2001;61(6):721-6.
2001: Ya Jun Hu; Konstantin V Korotkov; Rajendra Mehta; Dolph L Hatfield; C N Rotimi; A Luke; T Elaine Prewitt; Richard S Cooper; W Stock; E E Vokes; M Eileen Dolan; Vadim N Gladyshev; Alan M Diamond
Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene.
Cancer research 2001;61(5):2307-10.
2001: Reginald Ewesuedo; Lynette R Wilson; Henry S Friedman; Robert C Moschel; M Eileen Dolan
Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice.
Cancer chemotherapy and pharmacology 2001;47(1):63-9.
2000: Laurence D Rhines; Prakash Sampath; M Eileen Dolan; Betty M. Tyler; Henry Brem; Jon D Weingart
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Cancer research 2000;60(22):6307-10.
2000: Henry S Friedman; James Pluda; Jennifer A Quinn; Reginald Ewesuedo; L Long; Allan H Friedman; Ilkcan Cokgor; O Michael Colvin; Michael M Haglund; DM Ashley; Jeremy Rich; J Sampson; Anthony E Pegg; Robert C Moschel; Roger E McLendon; James M Provenzale; ES Stewart; Sandra Tourt-Uhlig; AM Garcia-Turner; James E Herndon; Darell D Bigner; M Eileen Dolan
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3522-8.
2000: Vikas J Patel; GB Elion; Peter J Houghton; Stephen T Keir; Anthony E Pegg; Stewart P Johnson; M Eileen Dolan; Darell D Bigner; Henry S Friedman
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4154-7.
2000: Y Cai; Michael H Wu; M Xu-Welliver; Anthony E Pegg; Susan M Ludeman; M Eileen Dolan
Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cancer research 2000;60(19):5464-9.
2000: L Long; Stacey L Berg; S K Roy; Cynthia McCully; H W Song-Yoo; Robert C Moschel; FRANK BALIS; M Eileen Dolan
Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3662-9.
2000: Richard L Schilsky; M Eileen Dolan; Donna Bertucci; Reginald Ewesuedo; Nicholas J Vogelzang; Sridhar Mani; Lynette R Wilson; Mark J Ratain
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3025-31.
2000: Everett E Vokes; Merrill S Kies; Daniel J Haraf; Kerstin M Stenson; Marcy A List; Rod A Humerickhouse; M Eileen Dolan; Harold Pelzer; L Sulzen; Mary Ellyn Witt; Y C Hsieh; Bharat B Mittal; Ralph R Weichselbaum
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(8):1652-61.
2000: Rod A Humerickhouse; K Lohrbach; L Li; W F Bosron; M Eileen Dolan
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Cancer research 2000;60(5):1189-92.
2000: Steven J Chmura; M Eileen Dolan; A Cha; Helena J Mauceri; Donald Kufe; Ralph R Weichselbaum
In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):737-42.
2000: Reginald Ewesuedo; M Eileen Dolan
Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat.
Cancer chemotherapy and pharmacology 2000;46(2):150-5.
2000: Stephen T Keir; M Eileen Dolan; Anthony E Pegg; AA Lawless; Robert C Moschel; Darell D Bigner; Henry S Friedman
O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.
Cancer chemotherapy and pharmacology 2000;45(6):437-40.
1999: Ramesh Wali; SF Skarosi; John Hart; Y Zhang; M Eileen Dolan; Robert C Moschel; Lan Nguyen; Reba Mustafi; Thomas A Brasitus; Marc Bissonnette
Inhibition of O(6)-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats.
Carcinogenesis 1999;20(12):2355-60.
1999: M Eileen Dolan; BL McRae; E Ferries-Rowe; M Belanich; Gijs A van Seventer; J Guitart; D Pezen; T M Kuzel; Daniel B Yarosh
O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(8):2059-64.
1999: Michael P Gamcsik; M Eileen Dolan; B S Andersson; D Murray
Mechanisms of resistance to the toxicity of cyclophosphamide.
Current pharmaceutical design 1999;5(8):587-605.
1999: Y Cai; Michael H Wu; Susan M Ludeman; David J Grdina; M Eileen Dolan
Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity.
Cancer research 1999;59(13):3059-63.
1999: Rod A Humerickhouse; M Eileen Dolan; Daniel J Haraf; Bruce E Brockstein; Kerstin M Stenson; Merrill S Kies; L Sulzen; Mark J Ratain; Everett E Vokes
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):291-8.
1999: Henry S Friedman; Anthony E Pegg; Stewart P Johnson; Natalia A Loktionova; M Eileen Dolan; Paul Modrich; Robert C Moschel; Robert F Struck; T P Brent; Susan M Ludeman; Nancy S Bullock; C Kilborn; Stephen T Keir; Q Dong; Darell D Bigner; O Michael Colvin
Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.
Cancer chemotherapy and pharmacology 1999;43(1):80-5.
1999: Michael H Wu; K E Lohrbach; Olufunmilayo I Olopade; Demetrius M Kokkinakis; Henry S Friedman; M Eileen Dolan
Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):209-13.
1998: Henry S Friedman; Demetrius M Kokkinakis; James Pluda; Allan H Friedman; Ilkcan Cokgor; Michael M Haglund; DM Ashley; Jeremy Rich; M Eileen Dolan; Anthony E Pegg; Robert C Moschel; Roger E McLendon; T Kerby; James E Herndon; Darell D Bigner; S Clifford Schold
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3570-5.
1998: M Eileen Dolan; Benjamin Frydman; Craig Thompson; Alan M Diamond; B J Garbiras; A R Safa; William T Beck; Laurence J Marton
Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents.
Anti-cancer drugs 1998;9(5):437-48.
1998: M Eileen Dolan; S K Roy; B J Garbiras; Paul R Helft; P Paras; M Y Chae; Robert C Moschel; Anthony E Pegg
O6-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O6-benzylguanine derivatives and their rate of hydrolysis by cellular esterases.
Biochemical pharmacology 1998;55(10):1701-9.
1998: M Eileen Dolan; S K Roy; AA Fasanmade; P R Paras; Richard L Schilsky; Mark J Ratain
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1803-10.
1998: Gregory P Zagaja; M Shrivastav; M J Fleig; Laurence J Marton; Carrie W Rinker-Schaeffer; M Eileen Dolan
Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo.
Cancer chemotherapy and pharmacology 1998;41(6):505-12.
1997: M Eileen Dolan; Anthony E Pegg
O6-benzylguanine and its role in chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):837-47.
1997: SN Kurpad; M Eileen Dolan; R E McLendon; G E Archer; Robert C Moschel; Anthony E Pegg; D D Bigner; H S Friedman
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Cancer chemotherapy and pharmacology 1997;39(4):307-16.
1996: S K Roy; Robert C Moschel; M Eileen Dolan
Pharmacokinetics and metabolism in rats of 2,4-diamino-6-benzyloxy-5- nitrosopyrimidine, an inactivator of O6-alkylguanine-DNA alkyltransferase.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(11):1205-11.
1996: Everett E Vokes; R Mick; Merrill S Kies; M Eileen Dolan; D Malone; I Athanasiadis; Daniel J Haraf; Mark F. Kozloff; Ralph R Weichselbaum; Mark J Ratain
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1663-71.
1996: Gini F Fleming; Everett E Vokes; John B Buse; R Mick; J Dushay; D Levitan; M Eileen Dolan
Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus.
Cancer chemotherapy and pharmacology 1996;37(6):569-73.
1996: M Belanich; T Randall; M A Pastor; Jeannie Kibitel; L G Alas; M Eileen Dolan; S C Schold; M Gander; F J Lejeune; Benjamin F L Li; A B White; Patricia Wasserman; M L Citron; Daniel B Yarosh
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
Cancer chemotherapy and pharmacology 1996;37(6):547-55.
1995: S K Roy; E Gupta; M Eileen Dolan
Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(12):1394-9.
1995: S K Roy; K R Korzekwa; F J Gonzalez; Robert C Moschel; M Eileen Dolan
Human liver oxidative metabolism of O6-benzylguanine.
Biochemical pharmacology 1995;50(9):1385-9.
1995: Anthony E Pegg; K Swenn; M Y Chae; M Eileen Dolan; Robert C Moschel
Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea.
Biochemical pharmacology 1995;50(8):1141-8.
1995: E Gupta; Olufunmilayo I Olopade; Mark J Ratain; R Mick; T M Baker; F K Berezin; A B Benson; M Eileen Dolan
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(10):1133-8.
1995: Henry S Friedman; M Eileen Dolan; Anthony E Pegg; S Marcelli; Stephen T Keir; J J Catino; Darell D Bigner; S Clifford Schold
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Cancer research 1995;55(13):2853-7.
1995: M Y Chae; K Swenn; Sreenivas Kanugula; M Eileen Dolan; Anthony E Pegg; Robert C Moschel
8-Substituted O6-benzylguanine, substituted 6(4)-(benzyloxy)pyrimidine, and related derivatives as inactivators of human O6-alkylguanine-DNA alkyltransferase.
Journal of medicinal chemistry 1995;38(2):359-65.
1995: Anthony E Pegg; M Eileen Dolan; Robert C Moschel
Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.
Progress in nucleic acid research and molecular biology 1995;51():167-223.
1994: M Eileen Dolan; M Y Chae; Anthony E Pegg; J H Mullen; Henry S Friedman; Robert C Moschel
Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase.
Cancer research 1994;54(19):5123-30.
1994: M Eileen Dolan; M J Fleig; Burt Feuerstein; H S Basu; GD Luk; Robert A Casero; L J Marton
Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts.
Cancer research 1994;54(17):4698-702.
1994: Henry S Friedman; M Eileen Dolan; Scott H Kaufmann; O Michael Colvin; O W Griffith; Robert C Moschel; S Clifford Schold; Darell D Bigner; Francis Ali-Osman
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Cancer research 1994;54(13):3487-93.
1994: M Y Chae; M G McDougall; M Eileen Dolan; K Swenn; Anthony E Pegg; Robert C Moschel
Substituted O6-benzylguanine derivatives and their inactivation of human O6-alkylguanine-DNA alkyltransferase.
Journal of medicinal chemistry 1994;37(3):342-7.
1994: M Eileen Dolan; Anthony E Pegg; Robert C Moschel; B R Vishnuvajjala; K P Flora; M R Grever; Henry S Friedman
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.
Cancer chemotherapy and pharmacology 1994;35(2):121-6.
1994: R B Mitchell; M Eileen Dolan; Linda Janisch; Nicholas J Vogelzang; Mark J Ratain; Richard L Schilsky
Sequential therapy with dacarbazine and carmustine: a phase I study.
Cancer chemotherapy and pharmacology 1994;34(6):509-14.
1993: Anthony E Pegg; M Boosalis; Leona D Samson; Robert C Moschel; T L Byers; K Swenn; M Eileen Dolan
Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine.
Biochemistry 1993;32(45):11998-2006.
1993: M Eileen Dolan; Anthony E Pegg; Robert C Moschel; G B Grindey
Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
Biochemical pharmacology 1993;46(2):285-90.
1993: R F Jacoby; Merry J G Bolt; M Eileen Dolan; G Otto; Pradeep K Dudeja; Michael D Sitrin; Thomas A Brasitus
Supplemental dietary calcium fails to alter the acute effects of 1,2-dimethylhydrazine on O6-methylguanine, O6-alkylguanine-DNA alkyltransferase and cellular proliferation in the rat colon.
Carcinogenesis 1993;14(6):1175-9.
1993: R E Bishop; L L Dunn; Gary T Pauly; M Eileen Dolan; Robert C Moschel
The role of O6-alkylguanine-DNA alkyltransferase in protecting Rat4 cells against the mutagenic effects of O6-substituted guanine residues incorporated in codon 12 of the H-ras gene.
Carcinogenesis 1993;14(4):593-8.
1993: M Eileen Dolan; Anthony E Pegg; N D Biser; Robert C Moschel; H F English
Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer.
Cancer chemotherapy and pharmacology 1993;32(3):221-5.
1993: R B Mitchell; M Eileen Dolan
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Cancer chemotherapy and pharmacology 1993;32(1):59-63.
1993: G M Felker; Henry S Friedman; M Eileen Dolan; Robert C Moschel; C Schold
Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Cancer chemotherapy and pharmacology 1993;32(6):471-6.
1992: Henry S Friedman; M Eileen Dolan; Robert C Moschel; Anthony E Pegg; G M Felker; Jeremy Rich; Darell D Bigner; S Clifford Schold
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
Journal of the National Cancer Institute 1992;84(24):1926-31.
1992: Robert C Moschel; M G McDougall; M Eileen Dolan; L Stine; Anthony E Pegg
Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase.
Journal of medicinal chemistry 1992;35(23):4486-91.
1992: R B Mitchell; Robert C Moschel; M Eileen Dolan
Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
Cancer research 1992;52(5):1171-5.
1991: M Eileen Dolan; Anthony E Pegg; L L Dumenco; Robert C Moschel; S L Gerson
Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine.
Carcinogenesis 1991;12(12):2305-9.
1991: Anthony E Pegg; L Wiest; C Mummert; L Stine; Robert C Moschel; M Eileen Dolan
Use of antibodies to human O6-alkylguanine-DNA alkyltransferase to study the content of this protein in cells treated with O6-benzylguanine or N-methyl-N'-nitro-N-nitrosoguanidine.
Carcinogenesis 1991;12(9):1679-83.
1991: Anthony E Pegg; L Wiest; C Mummert; M Eileen Dolan
Production of antibodies to peptide sequences present in human O6-alkylguanine-DNA alkyltransferase and their use to detect this protein in cell extracts.
Carcinogenesis 1991;12(9):1671-7.
1991: M Eileen Dolan; R B Mitchell; C Mummert; Robert C Moschel; Anthony E Pegg
Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.
Cancer research 1991;51(13):3367-72.
1990: M Eileen Dolan; Robert C Moschel; Anthony E Pegg
Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(14):5368-72.
1990: M Eileen Dolan; L Stine; R B Mitchell; Robert C Moschel; Anthony E Pegg
Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.
Cancer communications 1990;2(11):371-7.
1989: M Eileen Dolan; L Norbeck; C Clyde; N K Hora; L C Erickson; Anthony E Pegg
Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents.
Carcinogenesis 1989;10(9):1613-9.
1989: M Eileen Dolan; G L Larkin; H F English; Anthony E Pegg
Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine.
Cancer chemotherapy and pharmacology 1989;25(2):103-8.
1988: M Eileen Dolan; M Oplinger; Anthony E Pegg
Sequence specificity of guanine alkylation and repair.
Carcinogenesis 1988;9(11):2139-43.
1988: M Eileen Dolan; Anthony E Pegg; N K Hora; L C Erickson
Effect of O6-methylguanine on DNA interstrand cross-link formation by chloroethylnitrosoureas and 2-chloroethyl(methylsulfonyl)methanesulfonate.
Cancer research 1988;48(13):3603-6.
1988: M Eileen Dolan; D Scicchitano; Anthony E Pegg
Use of oligodeoxynucleotides containing O6-alkylguanine for the assay of O6-alkylguanine-DNA-alkyltransferase activity.
Cancer research 1988;48(5):1184-8.
1988: M Eileen Dolan; M Oplinger; Anthony E Pegg
Use of a dodecadeoxynucleotide to study repair of the O4-methylthymine lesion.
Mutation research 1988;193(2):131-7.
1988: Anthony E Pegg; K Morimoto; M Eileen Dolan
Investigation of the specificity of O6-alkylguanine-DNA-alkyltransferase.
Chemico-biological interactions 1988;65(3):275-81.
1987: Anthony E Pegg; D Scicchitano; K Morimoto; M Eileen Dolan
Specificity of O6-alkylguanine-DNA alkyltransferase.
IARC scientific publications 1987;(84):30-4.
1987: Anthony E Pegg; M Eileen Dolan
Properties and assay of mammalian O6-alkylguanine-DNA alkyltransferase.
Pharmacology & therapeutics 1987;34(2):167-79.
1985: Anthony E Pegg; M Eileen Dolan; D Scicchitano; K Morimoto
Studies of the repair of O6-alkylguanine and O4-alkylthymine in DNA by alkyltransferases from mammalian cells and bacteria.
Environmental health perspectives 1985;62():109-14.
1985: K Morimoto; M Eileen Dolan; D Scicchitano; Anthony E Pegg
Repair of O6-propylguanine and O6-butylguanine in DNA by O6-alkylguanine-DNA alkyltransferases from rat liver and E. coli.
Carcinogenesis 1985;6(7):1027-31.
1984: Anthony E Pegg; D Scicchitano; M Eileen Dolan
Comparison of the rates of repair of O6-alkylguanines in DNA by rat liver and bacterial O6-alkylguanine-DNA alkyltransferase.
Cancer research 1984;44(9):3806-11.
1984: M Eileen Dolan; D Scicchitano; B Singer; Anthony E Pegg
Comparison of repair of methylated pyrimidines in poly(dT) by extracts from rat liver and Escherichia coli.
Biochemical and biophysical research communications 1984;123(1):324-30.